Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-09-27
2005-09-27
Russel, Jeffrey Edwin (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S015800, C514S016700, C514S017400, C514S018700, C514S019300
Reexamination Certificate
active
06949514
ABSTRACT:
A method for treating subjects with abnormal cell proliferation is provided. The method involves administering to subjects in need of such treatment an effective amount of an agent of Formula I, to inhibit cell proliferation such as that associated with tumor growth and metastasis. A method for inhibiting angiogenesis in an abnormal proliferative cell mass by the administration of an agent of Formula I is also provided.
REFERENCES:
patent: 4318904 (1982-03-01), Shaw et al.
patent: 4443609 (1984-04-01), Oude Alink et al.
patent: 4499082 (1985-02-01), Shenvi et al.
patent: 4582821 (1986-04-01), Kettner et al.
patent: 4636492 (1987-01-01), Kettner et al.
patent: 4644055 (1987-02-01), Kettner et al.
patent: 4652552 (1987-03-01), Kettner et al.
patent: 4935493 (1990-06-01), Bachovchin et al.
patent: 4963655 (1990-10-01), Kinder et al.
patent: 5093477 (1992-03-01), Mölling et al.
patent: 5187157 (1993-02-01), Kettner et al.
patent: 5215926 (1993-06-01), Etchells, III et al.
patent: 5242904 (1993-09-01), Kettner et al.
patent: 5250720 (1993-10-01), Kettner et al.
patent: 5288707 (1994-02-01), Metternich
patent: 5296604 (1994-03-01), Hanko et al.
patent: 5329028 (1994-07-01), Ashkenazi et al.
patent: 5378624 (1995-01-01), Berenson et al.
patent: 5384410 (1995-01-01), Kettner
patent: 5444049 (1995-08-01), de Nanteuil et al.
patent: 5462928 (1995-10-01), Bachovchin et al.
patent: 5506130 (1996-04-01), Peterson et al.
patent: 5527923 (1996-06-01), Klingler et al.
patent: 5543396 (1996-08-01), Powers et al.
patent: 5554728 (1996-09-01), Basava et al.
patent: 5587299 (1996-12-01), Rettig et al.
patent: 5635386 (1997-06-01), Palsson et al.
patent: 5635387 (1997-06-01), Fei et al.
patent: 5639725 (1997-06-01), O'Reilly et al.
patent: 5646043 (1997-07-01), Emerson et al.
patent: 5753230 (1998-05-01), Brooks et al.
patent: 5767242 (1998-06-01), Zimmermann et al.
patent: 5854205 (1998-12-01), O'Reilly et al.
patent: 5854221 (1998-12-01), Cao et al.
patent: 5965373 (1999-10-01), Zimmermann et al.
patent: 5965532 (1999-10-01), Bachovchin
patent: 6040145 (2000-03-01), Huber et al.
patent: 6090786 (2000-07-01), Augustyns et al.
patent: 6100234 (2000-08-01), Huber et al.
patent: 6258597 (2001-07-01), Bachovchin et al.
patent: 6265551 (2001-07-01), Duke-Cohan et al.
patent: 6300314 (2001-10-01), Wallner et al.
patent: 6355614 (2002-03-01), Wallner
patent: 6503882 (2003-01-01), Huber et al.
patent: 6692753 (2004-02-01), Huber et al.
patent: 6703238 (2004-03-01), Bachovchin et al.
patent: 6770628 (2004-08-01), Wallner et al.
patent: 2002/0034789 (2002-03-01), Zimmermann et al.
patent: 2003/0130199 (2003-07-01), von Hoersten et al.
patent: 2003/0212044 (2003-11-01), Huber et al.
patent: 2004/0077601 (2004-04-01), Adams et al.
patent: 2004/0152192 (2004-08-01), Bachovchin et al.
patent: 729369 (1997-10-01), None
patent: DD 158109 (1982-12-01), None
patent: DD 270382 (1989-07-01), None
patent: DD 296075 (1991-11-01), None
patent: 0356223 (1990-02-01), None
patent: 0371467 (1990-06-01), None
patent: 0471651 (1992-02-01), None
patent: 0481311 (1992-04-01), None
patent: 0615978 (1994-09-01), None
patent: 0420913 (1995-11-01), None
patent: 0688788 (1995-12-01), None
patent: 335543 (2001-03-01), None
patent: WO89/03223 (1989-04-01), None
patent: WO91/16339 (1991-10-01), None
patent: WO91/17767 (1991-11-01), None
patent: WO92/12140 (1992-07-01), None
patent: WO92/17490 (1992-10-01), None
patent: WO93/02057 (1993-02-01), None
patent: WO93/05011 (1993-03-01), None
patent: WO93/08259 (1993-04-01), None
patent: WO93/10127 (1993-05-01), None
patent: WO93/16102 (1993-08-01), None
patent: WO94/03055 (1994-02-01), None
patent: WO94/09132 (1994-04-01), None
patent: WO94/20526 (1994-09-01), None
patent: WO94/25873 (1994-11-01), None
patent: WO94/28915 (1994-12-01), None
patent: WO94/29335 (1994-12-01), None
patent: WO95/11689 (1995-05-01), None
patent: WO95/12618 (1995-05-01), None
patent: WO95/15309 (1995-06-01), None
patent: WO95/29190 (1995-11-01), None
patent: WO 95/29233 (1995-11-01), None
patent: WO95/29691 (1995-11-01), None
patent: WO95/34538 (1995-12-01), None
patent: WO96/40263 (1996-12-01), None
patent: WO96/40858 (1996-12-01), None
patent: WO97/34927 (1997-09-01), None
patent: WO98/00439 (1998-01-01), None
patent: WO98/25644 (1998-06-01), None
patent: WO98/50046 (1998-11-01), None
patent: WO98/50066 (1998-11-01), None
patent: WO99/16864 (1999-04-01), None
patent: WO 99/47152 (1999-09-01), None
patent: WO 99/56753 (1999-11-01), None
patent: WO99/62914 (1999-12-01), None
patent: WO00/10549 (2000-03-01), None
patent: WO 00/71135 (2000-11-01), None
patent: WO 04/004658 (2004-01-01), None
patent: WO 04/004661 (2004-01-01), None
Ariga, N. et al., “Stromal expression of fibroblast activation protein/seprase, a cell membrane serine proteinase and gelatinase, is associated with longer survival in patients with invasive ductal carcinoma of breast”Int. J. Cancer, Jan. 20, 2001, 95(1):67-72.
Goldstein, L.A., et al., “Identification of an Alternatively Spliced Seprase mRNA that Encodes a Novel Intracellular Isoform”The Journal of Biological Chemistry, vol. 275, No. 4, Jan., 2000, pp. 2554-2559.
McCaughan, G.W. et al., “Molecular pathogenesis of liver disease: an approach to hepatic inflammation, cirrhosis and liver transplant tolerance”Immunological Reviews 2000, vol. 174: 172-191.
Park, J.E., et al., “Fibroblast Activation Protein, a Dual Specificity Serine Protease Expressed in Reactive Human Tumor Stromal Fibroblasts”The Journal of Biological Chemistry, vol. 274, No. 51, Dec. 1999,pp. 36505-36512.
Rettig, W.J., et al., “Differential Expression of Cell Surface Antigens and Glial Fibrillary Acidic Protein in Human Astrocytoma Subsets”Cancer Research46:6406-6412, Dec. 1986.
Sun, S. et al., “Expression purification, and kinetic characterization of full-length human fibroblast activation protein”Protein Expr. Purif. Mar. 2002, 24(2):274-281 (Abstract Only).
Aguila, H.L., et al., “From Stem Cells To Lymphocytes: Biology And Transplantation”,Immun Rev, (1997), 157:13-40.
Ansorge, et al., “CD26/Dipeptidyl Peptidase IV in Lymphocyte Growth Regulation”,Adv Exp Med Biol. (1997) 421:127-40.
Austin, D.J., et al., “Proximity Versus Allostery: The Role Of Regulated Protein Dimerization In Biology”,Chemistry&Biology, (1994), 1:131-136.
Bachovchin, W.W., et al., “Inhibition Of Igal Proteinases From Neisseria Gonorrhoeac And Hemophilus Hemophilus Influenzae By Peptide Prolyl Boronic Acids”,J Biol Chem, (1990), 265: 3738-3743.
Bailey, P.D., “An Introduction To Peptide Chemistry”,Wiley Publishers, (1990), 1-81.
Barton, R.W.J., et al., “Binding Of The T Cell Activation Monoclonal Antibody Tal To Dipeptidyl Peptidase IV”,J. of Leukocyte Biology48:291-296 (1990).Abstract.
Baugh, R., et al., “Role and Potential Therapeutic Value of Proteinase Inhibitors in Tissue Destruction”Proteinases And Tumor Invasion, (1980), 165:157-179.
Blezinger, et al., “Systemic Inhibition Of Tumor Growth And Tumor Metastases By Intramuscular Administration Of The Endostatin Gene”Nature Biotech., (199) 17:343-348.
Blumenstein et al., Biochem. Biophys. Res. Comm. 163(2):980-987.
Bodansky, M., “Peptide Chemistry, A Practical Textbook”,Springer-Verlag, (1988) 1-9.
Bodansky, M., “Principles Of Peptide Synthesis”,Springer-Verlag, (1984), vol. 16.
Bodansky, M., “The Practice Of Peptide Synthesis”,Springer-Verlag, (1984), vol. 21.
Boros, L.G., et al., “Fluoroolefin Peptide Isosteres-Tools For Controlling Peptide Conformations”,Tetrahedron Letters, (1994), 35:6033-6036.
Brady, L., and Dodson, G., “Reflections On A Peptide”,Nature, (1994), 368:692-693.
Brander, et al.,J. Immunol. 155 (5):2670-2678 (Sep. 1, 1995),Abstract.
Bristol, L.A., et al., “Characterization Of A Novel Rat Thymocyte Costimulating Antigen By The Monoclonal Antibody 1.3”,J. Immunol. 148:332-338 (1992).Abstract.
Bristol,
Miller Glenn
Wallner Barbara
Point Therapeutics, Inc.
Russel Jeffrey Edwin
Wolf Greenfield & Sacks P.C.
LandOfFree
Anti-tumor agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-tumor agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-tumor agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3412817